GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CRDF · Jun 30, 2025

Cardiff Oncology, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000950170-25-099610General Corporate
Operating cash generation42thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-6882.64% · OPTIONAL · VALID

Revenue growth13thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

-25.77% · CORE · VALID

Operating margin17thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-12212.40% · CORE · VALID

SBC intensity92thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1390.91% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Increased
Previous
-11737.61%
Current
-6882.64%
Delta
4854.97%
Growth Increased
Previous
-46.83%
Current
-25.77%
Delta
21.06%
Profitability Increased
Previous
-13194.50%
Current
-12212.40%
Delta
982.10%
Sbc Intensity Increased
Previous
1252.29%
Current
1390.91%
Delta
138.62%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.